Lijun Xia, MD, PhD
Technical Founder & Inventor
Dr. Xia is a renowned scientist and practicing hematologist/oncologist. As Chair of the Cardiovascular Department at the Oklahoma Medical Research Foundation, he holds the prestigious Merrick Foundation Chair in Biomedical Research. His research on O-glycans has led to the development of Targazyme’s promising candidates, TZ101 and TZ102. With a strong publication record and significant research funding, Dr. Xia is highly influential in the field.
Dr. Xia holds the prestigious Merrick Foundation Chair in Biomedical Research and serves as the Chair of the Cardiovascular Department at the Oklahoma Medical Research Foundation. With a research career spanning over two decades, he has made significant contributions to the study of O-glycans. His pioneering work in this field led to the development of Targazyme’s promising candidates, TZ101 and TZ102. Dr. Xia is not only a respected scientist but also a practicing hematologist/oncologist.
As one of the co-founders of Targazyme Inc., Dr. Xia has played a pivotal role in translating his research findings into tangible advancements in healthcare. He is widely recognized as one of the most influential and highly cited scientists in the field of glycosylation and O-glycans. His exceptional work has secured several million dollars in research funding, further enabling his groundbreaking investigations.
Dr. Xia obtained his MD and PhD degrees in China and currently serves as the Program Chair of the Cardiovascular Biology Research Program at The Oklahoma Medical Research Foundation. In addition, he serves as the Principal Investigator of the COBRE- Center for Cellular Metabolism Research in Oklahoma.